ArticleMedicine2026
Causal association between antidiabetic drug targets and risk of Bell's palsy: A 2-sample Mendelian randomization study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To investigate the causal effects of antidiabetic drug targets on Bell's palsy risk using Mendelian randomization (MR), addressing limitations of observational studies and informing therapeutic strategies for diabetic patients. A 2-sample MR analysis was conducted using genetic instruments for 5 major antidiabetic drug classes: sulfonylureas (ABCC8/KCNJ11), metformin (GPD1), thiazolidinediones (PPARG), GLP1-RAs (GLP1R), and SGLTi (SLC5A1/2). Instrumental variables were selected from cis-regions (±500 kb) of target genes using HbA1c-associated single nucleotide polymorphisms (GWAS ID: ebi-a-GCST90014006) with stringent clumping (P < 5 × 10-8, r2 < 0.2) and F-statistic > 10 to ensure robustness. Bell's palsy data were sourced from FinnGen (finn-b-G6_BELLPA) including. Causal effects were assessed via inverse variance weighted, MR-Egger, and weighted median methods, complemented by sensitivity analyses (MR-Pleiotropy RESidual Sum and Outlier, Cochran's Q). Genetically proxied sulfonylurea (via ABCC8/KCNJ11) and metformin (via GPD1) targets exhibited significant protective effects against Bell's palsy, with odds ratios of 0.19 (95% CI: 0.04-0.92, P = .039) and 0.16 (0.03-0.87, P = .034), respectively. Sensitivity analyses confirmed minimal pleiotropy (MR-Egger intercept P > .05) and heterogeneity (Cochran's Q P > .05). No associations were observed for thiazolidinediones, GLP1-RAs, or SGLTi. Scatter plots and inverse variance weighted median concordance supported robustness for ABCC8/KCNJ11, though limited single nucleotide polymorphisms for GPD1 warranted cautious interpretation. This MR analysis provides genetic evidence that sulfonylureas and metformin may confer neuroprotection against Bell's palsy, supporting potential repurposing of these agents to mitigate neurological complications in diabetic patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.